HomeInsightsStock Comparison

Aurobindo Pharma Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Aurobindo Pharma Ltd vs Dr Reddys Laboratories Ltd Stock Comparison

Last Updated on: May 03, 2025

Key Highlights

  • The Latest Trading Price of Aurobindo Pharma Ltd is ₹ 1212 as of 02 May 15:30.
  • The P/E Ratio of Aurobindo Pharma Ltd changed from 8.5 on March 2020 to 20.1 on March 2024 . This represents a CAGR of 18.78% over 5 yearsThe P/E Ratio of Dr Reddys Laboratories Ltd changed from 25.6 on March 2020 to 18.4 on March 2024 . This represents a CAGR of -6.39% over 5 years.
  • The Market Cap of Aurobindo Pharma Ltd changed from ₹ 24202 crore on March 2020 to ₹ 63835 crore on March 2024 . This represents a CAGR of 21.41% over 5 yearsThe Market Cap of Dr Reddys Laboratories Ltd changed from ₹ 51797 crore on March 2020 to ₹ 102679 crore on March 2024 . This represents a CAGR of 14.67% over 5 years.
  • The revenue of Aurobindo Pharma Ltd for the Dec '24 is ₹ 8137 crore as compare to the Sep '24 revenue of ₹ 7932 crore. This represent the growth of 2.58% The revenue of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 8535 crore as compare to the Sep '24 revenue of ₹ 8351 crore. This represent the growth of 2.2%.
  • The ebitda of Aurobindo Pharma Ltd for the Dec '24 is ₹ 1736 crore as compare to the Sep '24 ebitda of ₹ 1702 crore. This represent the growth of 2.02% The ebitda of Dr Reddys Laboratories Ltd for the Dec '24 is ₹ 2427 crore as compare to the Sep '24 ebitda of ₹ 2390 crore. This represent the growth of 1.56%.
  • The net profit of Aurobindo Pharma Ltd changed from ₹ 569.71 crore to ₹ 845.57 crore over 7 quarters. This represents a CAGR of 25.31% The net profit of Dr Reddys Laboratories Ltd changed from ₹ 1405 crore to ₹ 1404 crore over 7 quarters. This represents a CAGR of -0.03% .
  • The Dividend Payout of Aurobindo Pharma Ltd changed from 9.37 % on March 2020 to 13.49 % on March 2024 . This represents a CAGR of 7.56% over 5 yearsThe Dividend Payout of Dr Reddys Laboratories Ltd changed from 14.14 % on March 2020 to 15.37 % on March 2024 . This represents a CAGR of 1.68% over 5 years.

Share Price

* All values are in Rupees

P/E Ratio Over Time

No data available

Market Cap Over Time

No data available

* All values are in crore

Historical Share Prices

* All values are in Rupees

Revenue Over Time

No data available

* All values are in crore

EBITDA Over Time

No data available

* All values are in crore

Net Profit Over Time

No data available

* All values are in crore

Dividend Payout Over Time

No data available

* All values are in %

About Aurobindo Pharma Ltd

  • Aurobindo Pharma Limited (APL), one of the world's top 5 manufacturers of semi synthetic penicillins was incorporated in 26th December 1986 as a private limited company.
  • Mr. P.V.Ramaprasad Reddy, Mr. K.Nityananda Reddy and a small, highly committed group of professionals founded it.
  • APL is developing, manufacturing and marketing active pharmaceutical ingredients (APIs also referred as bulk actives), intermediates and generic formulations.
  • The company's robust product portfolio is spread over 6 major product areas encompassing (Antibiotics, Anti-Retro Virals, CVS, CNS, Gastroenterologicals, and Anti-Allergics) with around 65 APIs in the non-antibiotics and over 55 APIs in the antibiotic segment and the World Health Organization (WHO), Geneva, has also approved Aurobindo's products.
  • APL is running with 24 manufacturing plants across the world conforming to GMP/ISO regulations and an extremely well equipped 9 R&D facilities.

About Dr Reddys Laboratories Ltd

  • Dr Reddy's Laboratories Limited (DRL) is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives.
  • Through its three businesses - Pharmaceutical Services &Active Ingredients, Global Generics and Proprietary Products - Dr. Reddy's offers a portfolio of products and services including Active Pharmaceutical Ingredients (APIs), custom pharmaceutical services, generics, biosimilars and differentiated formulations.
  • The company's major therapeutic areas of focus are gastrointestinal, cardiovascular, diabetology, oncology, pain management and dermatology.
  • Dr. Reddy's operates in markets across the globe.
  • Its major markets include - USA, India, Russia & CIS countries, and Europe. Dr Reddy's Laboratories Limited was incorporated in 1984 in Hyderabad.

Aurobindo Pharma Ltd News Hub

News

Aurobindo Pharma drops after fire incident at Kakinada facility

The incident, which occurred on 27 April 2025, has prompted a temporary suspension of oper...

Read more

29 Apr 2025 16:22

News

CuraTeQ Biologics s.r.o. receives positive opinion for biosimilar Dazublys' from EMA

CuraTeQ Biologics s.r.o., a wholly owned step-down subsidiary of Aurobindo Pharma, announc...

Read more

26 Apr 2025 13:58

News

Aurobindo Pharma rallies after arm receives USFDA nod for Dasatinib tablets

The drug is bioequivalent and therapeutically equivalent to the reference listed drug (RLD...

Read more

23 Apr 2025 12:05

News

Aurobindo Pharma rallies after receiving USFDA nod for Rivaroxaban tablets

The said drug is bioequivalent and therapeutically equivalent to the reference listed drug...

Read more

15 Apr 2025 10:07

News

Aurobindo Pharma gets USFDA nod for Rivaroxaban tablets

The said drug is bioequivalent and therapeutically equivalent to the reference listed drug...

Read more

14 Apr 2025 08:59

News

USFDA inspects Aurobindo Pharma's Raleigh Plant in North Carolina

Aurobindo Pharma announced that the United States Food and Drug Administration (USFDA) has...

Read more

11 Apr 2025 15:22

Dr Reddys Laboratories Ltd News Hub

News

Dr Reddys announces cessation of subsidiary in Louisiana

Dr. Reddy's Laboratories Inc., USA, a wholly owned subsidiary of the Company, has successf...

Read more

24 Mar 2025 13:48

News

Dr Reddys Laboratories to conduct board meeting

Dr Reddys Laboratories will hold a meeting of the Board of Directors of the Company on 9 M...

Read more

22 Mar 2025 11:01

News

Dr. Reddy's recalls Levetiracetam in 0.75% Sodium Chloride Injection 1,000 mg/100 mL in US

Dr. Reddy's Laboratories is recalling one Batch/Lot No: A1540076 of Levetiracetam in 0.75%...

Read more

13 Mar 2025 18:46

News

Dr Reddys Laboratories allots 11,250 equity shares under ESOS

Dr Reddys Laboratories has allotted 11,250 equity shares under ESOS on 06 March 2025. Powe...

Read more

06 Mar 2025 19:16

News

Dr Reddy's Lab gets EIR from USFDA for Hyderabad facility

The USFDA has classified the inspection as Voluntary Action Indicated (VAI) and confirmed ...

Read more

27 Feb 2025 09:57

News

Dr Reddys Laboratories allots 20,155 equity shares under ESOS

Dr Reddys Laboratories has allotted 20,155 equity shares of Re.1/- each of the Company, fu...

Read more

14 Feb 2025 18:24

SWOT Analysis Of Aurobindo Pharma Ltd

Strength

3

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

SWOT Analysis Of Dr Reddys Laboratories Ltd

Strength

2

S

Weakness

2

W

Opportunity

0

O

Threats

1

T

BlinkX Score for Aurobindo Pharma Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

BlinkX Score for Dr Reddys Laboratories Ltd

Revenue

Profitability

Affordability

Liquidity

Dividend

FAQs for the comparison of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd

Which company has a larger market capitalization, Aurobindo Pharma Ltd or Dr Reddys Laboratories Ltd?

Market cap of Aurobindo Pharma Ltd is 71,021 Cr while Market cap of Dr Reddys Laboratories Ltd is 98,707 Cr

What are the key factors driving the stock performance of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd?

The stock performance of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd?

As of May 3, 2025, the Aurobindo Pharma Ltd stock price is INR ₹1212.1. On the other hand, Dr Reddys Laboratories Ltd stock price is INR ₹1182.9.

How do dividend payouts of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd compare?

To compare the dividend payouts of Aurobindo Pharma Ltd and Dr Reddys Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.
Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.
up arrow
Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions

Join the

Future of Trading

with BlinkX

#ItsATraderThing

Open Trading Account
Verify your phone
+91
*By signing up you agree to our terms & conditions